Scientific Advisory Board

Dr. Quezada is a Professor of Cancer Immunology and Immunotherapy at University College London Cancer Institute. Dr. Quezada’s research group focuses on the interplay between the immune system and cancer throughout tumor progression and immunotherapy. Dr. Quezada previously co-led the development of a first-in-class Treg-depleting anti-CD25 antibody at Tusk Therapeutics, which was acquired by Roche in 2018. He is the a scientific founder and the Chief Scientific Officer of Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T-cell therapies for cancer. Sergio is an internationally recognized leader in the field of cancer immunology, having previously received Dartmouth’s John W. Strohbern Medal for Excellence in Biomedical Research, the Cancer Research Institute New Investigator Award, a Cancer Research UK (CRUK) Career Development Fellowship, and a CRUK Senior Cancer Research Fellowship. He earned Ph.D. in immunology from Dartmouth Medical School and completed postdoctoral studies in the lab of Nobel Laureate Dr. James Allison at Memorial Sloan Kettering Cancer Center, where he studied mechanisms governing anti-tumor T-cell immunity.

Dr. Becher is a Professor at the University of Zurich where he serves as Chair of the Institute of Experimental Immunology. He is a leader in the fields of inflammation and cancer research, using state of the art technologies to better understand innate and adaptive immune mechanisms and cytokine networks. He has published more than 250 peer-reviewed papers in journals such as Nature, Cell, Immunity, Nature Medicine, and has been an editorial board member for major journals in his field. He is a ‘highly cited’ researcher for several consecutive years https://recognition.webofscience.com/awards/highly-cited/2021/. In recognition for his groundbreaking work, he has received numerous awards, including the 2021 Johann Anton Merck Award in the field of neuro-immunology and cancer and the 2019 Sobek Research Award, the most endowed prize for basic research in Europe for Multiple Sclerosis. Dr. Becher did his Ph.D. work at the Montreal Neurological Institute at McGill University in Canada and completed postdoctoral studies at Dartmouth Medical School.

Dr. Mooney is the Robert Pinkas Family Professor of Bioengineering in the Harvard School of Engineering and Applied Sciences, and a founding core faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. Dr. Mooney is a leader in the fields of drug delivery, and immuno-engineering, and his lab developed the first implantable biomaterial cancer vaccine that recruits and re-educates the immune system to destroy cancer cells. He has published over 400 peer-reviewed articles and is a ‘highly cited’ researcher for several consecutive years ( https://recognition.webofscience.com/awards/highly-cited/2021/ ). Dave has been issued numerous patents, several of which have been licensed to companies, resulting in successful commercial products. In 2019 he was rated one of the Top 10 translational researchers in biotech. He was elected to the National Academy of Engineering in 2010, the National Academy of Medicine in 2013, and as a Fellow of the National Academy of Inventors in 2017. He has a Ph.D. in chemical engineering from the Massachusetts Institute of Technology (under Dr Robert Langer) and completed his postdoctoral studies at Harvard University.

Dr. Redmond is Director of the Immune Monitoring Laboratory and Full Member at the Earle A. Chiles Research Institute (EACRI) at the Providence Cancer Institute. He is also an Adjunct Assistant Professor in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University. Dr. Redmond earned his Ph.D. in immunology at The Scripps Research Institute and completed postdoctoral training with a focus in tumor immunotherapy in Dr. Andrew Weinberg’s laboratory at the EACRI. Dr. Redmond has extensive experience with murine tumor models and, as Director of the EACRI Immune Monitoring Laboratory, oversees translational research efforts seeking to develop and implement state-of-the-art immune profiling assays. His goal is to identify biomarkers of response that may provide insight into the mechanisms by which immunotherapy improves outcomes in patients with advanced malignancies.